anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention describes antagonists for PDGF. The antagonists contain amino acids, and may be monomers or dimers. Especially preferred are dimers which bind the PDGF receptors, but prevent dimerization of the bound receptors. Dimerization is necessary for PDGF effect, hence the antagonistic effect. Also described are nucleic acid sequences for making the antagonists, as well as cell lines transfected with the material. The figure sets forth amino acid sequences for peptides eluted from PDGF-A HPLC experiments.
PURPOSE:To obtain a drug for administration through body cavity, effective in promoting the absorption of 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid (an anti-inflammatory analgesic antipyretic agent) through mucosa and improving bioavailability of the compound, by compounding a hydrogenated phospholipid to an oily substrate. CONSTITUTION:The objective agent for administration through body cavity can be produced by dispersing (A) 5-25pts.wt., preferably 15-25pts.wt. of the above compound of formula (general name: diflunisal) in a mixture of (B) 100pts.wt. of an oily substrate and (C) 0.1-10pts.wt., preferably 1-8pts.wt. of a hydrogenated phospholipid. The bioavailability of diflunisal through the mucosa of rectum, cavity, oral cavity of nose, etc., can be improved and the side effects appearing in the conventional oral administration can be avoided. The agent can be easily prepared, has high compatibility to the mucosa of living body and exhibits excellent absorbability of diflunisal.
Implementations are related to providing image selection suggestions. In some implementations, a method includes receiving first user input indicative of selection of one or more first images in an image library and determining one or more first image characteristics of the one or more first images. The method further includes identifying one or more second images in the image library. Each image of the one or more second images is associated with at least one second image characteristic that matches at least one of the one or more first image characteristics. The method further includes causing a user interface to be displayed. The user interface includes the one or more second images and enables selection of the one or more second images by a user.
A method for extracting  Hevea  Latex Polysaccharides (HLPs) from process effluent in the rubber manufacturing industry. The effluent obtained from the squeeze-milling of rubber coagula is optionally filtered in order to remove debris and various micro-organisms. The liquid is then concentrated, preferably by evaporation. Proteins are removed as much as possible and excess acidity, if any, is neutralized. Polysaccharides are then precipitated with an organic solvent and then collected. The final step is drying the precipitate to obtain the polysaccharide extract. Each step is performed at a temperature lower than about 100°C. The disclosure also provides for the use of such extract and of the composition comprising such extract in the manufacture of a medicament for the treatment of inflammation.
The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. Symptoms usually resolve over days when the combination is discontinued. This is typical of the interaction of meperidine and MAOIs. Other serious reactions (including severe agitation, hallucinations, and death) have been reported in patients receiving this combination (see CONTRAINDICATIONS). Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and selegiline and selective serotonin reuptake inhibitors and selegiline. (See WARNINGS for details.) One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).
Cancer remains a global health challenge, necessitating the exploration of novel therapeutic agents. Current treatment options are unable to overwhelm and cure the cancer burden. Hence, identifying new bioactive molecular entities with potent anticancer activity is the need of the hour. Ellagitannin Geraniin (GN) is one such evidence-based novel bioactive molecular entity (BME) available from different natural sources that can effectively combat cancer. This narrative review attempts to investigate the potential of BME-GN from 2005 to 2023 as an efficient molecular anti-cancer therapeutic against diverse cancers. We provide information on GN's pharmacological advantages, metabolite profile, and capacity to modulate multiple molecular targets involved in the hallmarks of cancer. Using the search terms "Geraniin," "Gallic acid," "Ellagitannin," "pharmacological properties," "health," "antioxidant," "apoptosis," "disease management," "anti-proliferative," "in vitro," "anti-inflammatory," "anti-angiogenic," "in vivo," and "clinical trials," We searched the scientific literature using Scopus, Web of Science, Google Scholar, and PubMed. We removed publications that included overlap or equivalent content and used the most recent review on each issue as our primary reference. From an initial pool of 430 articles, 52 studies met the search criteria. These studies collectively provide substantial in vitro, in vivo, and clinical evidence of GN's potential to combat diverse cancers. Mechanistic insights revealed its involvement in fostering apoptosis, anti-inflammatory, and modulation of key signalling pathways implicated in the hallmarks of cancer. GN's pleiotropic pharmacological and molecular therapeutic properties strongly suggest its potential as a promising anticancer agent.
The present invention discloses a modified composite microparticle, a manufacturing method thereof and a sunblock formulation thereof. The method comprises following steps. A natural plant is heated for a predetermine time in order to extract a first plant extracted liquid. The first plant extracted liquid is filtered through a filter film to obtain a filtered plant extracted liquid. The filtered plant extracted liquid is added with a modification solution and is then stirred at a stirring temperature to form a modified plant mixture solution. A precipitate of the modified plant mixture solution is collected by a centrifuge. After freeze-drying, the precipitate is ground for obtaining a modified composite microparticle and forming an inorganic particle on the surface of the modified composite microparticle.
In the Fitbit + Coaching Sessions arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.
Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.
Hypotension occurring under spinal anaesthesia (SBP \< 90mmHg) requires pharmacological treatment. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. The dose within this range will be decided by the attending anaesthetist. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
PROBLEM TO BE SOLVED: To obtain a composition never causing transfer of powder, excellent in water resistance, capable of comfortably applying, having good retaining force, capable of forming flexible coating free from tackiness and having gloss and useful for cosmetics by using a polymer dispersible to fat phase and a fat-soluble polymer. SOLUTION: This cosmetic composition for topical application comprises (A) a liquid fat phase (e.g. a carbon-containing oil derived from minerals, animals, plants or synthetic materials, a hydrocarbon-containing oil or a silicone oil) and (B) a coloring substance (e.g. to which filler, pigment or pearl brightener is added) and further contains (C) a polymer dispersible to the component A (e.g. a film-forming polymer such as polyurethane or polyurea in a form of disperse particles whose interface is stabilized with a stabilizer such as hydrocarbon-containing chain graft silicone polymer) and (D) a polymer soluble in the component A (e.g. a copolymer of an 8-22C alkene with vinylpyrrolidone).
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to physiotherapy, and can be used for treating osteoarthritis of joints. Magnetic therapy of the joints is performed, and the joints are treated with a medicinal product in the form of an aqueous solution of mineral salts. Magnetophoresis of the affected joints is therein performed as magnetic therapy. A pulse travelling magnetic field with a modulation frequency no more than 110 Hz and a magnetic induction of 15 to 20 mT combined with simultaneous application of the aqueous solution of mineral salts to the joints is used as magnetic emission. A solution of bischofite or a mineral water of a chloride-sulphide-calcium composition with a high content of magnesium ions is used as an aqueous solution of mineral salts. The time of combined exposure of the joint is 15 minutes for the first procedure with a gradual daily increase in the time of exposure up to 30 minutes by the 3rd procedure and a course of treatment of up to 10 procedures.EFFECT: increase in the effectiveness of physiotherapeutic treatment of osteoarthritis of joints due to the complex impact of magnetic therapy and applications of a solution of mineral salts on the affected joint.5 cl
CNTO 1959 is an experimental drug. In this study, CNTO 1959 will be tested to see if it may be useful in treating psoriasis. This disease causes inflammation of skin and nails. This is a Randomized (study drug assigned by chance), Double-blind (neither physician nor patient knows the name of the assigned drug), Placebo-controlled study of the experimental drug CNTO 1959 in both healthy patients as well as patients with psoriasis. This study will compare the effects (both good and bad) of CNTO 1959 to those of placebo. The purpose of this study is to evaluate the safety and potential side effects of CNTO 1959 given to healthy volunteers and patients with moderate to severe psoriasis. In addition, the investigators will measure how much study drug is in the blood following a dose of CNTO 1959, and determine if the body makes antibodies to it. (An antibody is a protein made by the body in response to a foreign substance). Safety assessments will be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (e.g., blood pressure), and the occurrence and severity of adverse events. This is the first time that CNTO 1959 will be studied in humans. There will be 2 parts to this study. The first part of this study will involve healthy volunteers, and the second part of the study will involve patients with psoriasis. About 47 healthy volunteers and 24 patients with moderate to severe psoriasis will take part in the study. Enrollment for the healthy volunteer part is closed as of 23SEP09. CNTO 1959 will be administered as either an intravenous (IV) infusion or subcutaneous (SC) injection. Duration of participation may be up to 28 weeks.
BACKGROUND: Thousands of units of whole blood (WB) and blood components are transfused daily to treat trauma patients. Improved methods for blood storage are critical to support trauma-related care. The Hemanext ONE® system offers a unique method for hypoxic storage of WB, with successfully demonstrated storage of clinically viable RBCs. This work evaluated the system for the storage of WB, focusing on platelet health and function.
STUDY DESIGN AND METHODS: WB was collected from healthy donors and processed through the Hemanext ONE® system. Hemoglobin oxygen saturation (HbSO2) levels of WB were depleted to 10%, 20%, or 30% of total HbSO2 and then stored in PVC bags sealed in oxygen-impermeable bags (except for normoxic control) with samples collected on days 1, 7, and 14 post-processing. Flow cytometry assessed the activation and apoptosis of platelets. Clot dynamics were assessed based on aggregometry and thromboelastography assays, as well as thrombin generation using a calibrated-automated thrombogram method.
RESULTS: Hypoxic storage conditions were maintained throughout the storage period. Hypoxia triggered increased lactate production, but pH changes were negligible compared to normoxic control. Storage at 10% HbSO2 had a significant impact on platelet function, resulting in increased activation and reduced clot formation and aggregation. These effects were less significant at 20% and 30% HbSO2.
DISCUSSION: This study indicates that platelets are sensitive to hypoxic storage and suffer significant metabolic and functional deterioration when stored at or below 10% HbSO2.
Participants will consume four low-quality protein containing meals per day (amounting to 1g/kg/day of protein) over a 10-day period. Each meal will contain 25:75 animal:plant protein with most of the plant protein from supplemental low-quality protein powder.
FIELD: medical microbiology.SUBSTANCE: described polyvalent vaccine against human leptospirosis contains as antigens strains of four leptospira serogroups: Leptospira interrogans Icterohaemorrhagiae copenhageni, Rat 2/466; L. interrogans Grippotyphosa grippotyphosa, Microtus arvalis 30/469; L. interrogans Pomona mozdok, 48B/470; L. interrogans Sejroe sejroe, Mus musculus 751/471. In accordance with the invention, the group of antigens is provided with an additional fifth strain of L. interrogans Canicola, No. 480 Udaloe, while as a result of the studies carried out, it was established that this additional strain in the composition of the experimental vaccine causes the formation of antibodies in protective titers of at least 1:100, which corresponds to the requirements applied to the concentrated inactivated liquid leptospirosis vaccine. A method for obtaining a polyvalent vaccine against human leptospirosis is presented, including the cultivation of the biomass of Leptospira on a liquid semi-synthetic storage medium with human blood proteins, inactivation with formaldehyde, concentration of the microbial mass by ultrafiltration on hollow polyamide fibers, purification of biomass from the components of the cultivation medium by double washing with physiological solution. In accordance with the invention, the standardization of microbial biomass was carried out by counting microbial cells, while the calculation was carried out according to the formula (1):, where K is the number of leptospira in 1 ml; 3570.4 - coefficient indicating how many times the area of distribution of the culture under glass exceeds the area of the field of view; 50 - coefficient indicating how many times the volume of 1 ml exceeds the volume of the test culture; M is the average number of leptospira in the field of view; analyzed five ampoules of the experimental vaccine, 0.02 ml each and viewed in the field of view of a dark-field microscope at a magnification of ×200; the result calculated by the formula was divided by 2, taking into account the dosage of the experimental vaccine and when determining the arithmetic mean value in a dose of 0.5 ml of the vaccine, which is not less than (20±2)×106microbial cells, it was concluded that the new experimental vaccine against leptospirosis meets the requirements, applied to the vaccine leptospirosis concentrated inactivated liquid used for the prevention of disease. The invention can be used to improve a multivalent vaccine against human leptospirosis.EFFECT: creation of a multivalent, improved leptospirosis vaccine, concentrated inactivated liquid for people with increased epidemiological efficiency.2 cl, 2 dwg
Ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes. Static stretching: 5 repetitions with 15 sec hold time of stretch.
Patients undergo TBI using IMRT BID on days -5 and -4 in the absence of disease progression or disease progression. Patients then receive cyclophosphamide on days -3 and -2 and undergo HSCT on day 0 in the absence of disease progression or unacceptable toxicity.
The invention relates to the use of an active substance complex comprised of (A) at least one carboxylic acid or the salts thereof according to formula (I), whereby n is a whole number between 0 and 9, the substituent R1 is selected from hydrogen, from a branched or unbranched C¿1?- to C19-alkyl group, from a branched or unbranched, single or multiple unsaturated C1- to C19-alkyl group or from a group of formula (II). The substituent R?2¿ represents a group of formula (III) or, if R1 is a group of formula (II), also represents a C¿4?- to C22-alkyl group or a group of formula (IV). The substituent R?3¿ represents a linear or branched C¿1?- to C20-alkyl group or a linear or branched, single or multiple unsaturated C1- to C21-alkyl group. The substituents R?4 to R5¿, independent of one another, represent hydrogen, a linear or branched C¿1?- to C21-alkyl group or a linear or branched, single or multiple unsaturated C1- to C20-alkyl group with the provision that at least one of the radicals R?4 or R5¿ represents hydrogen, and X represents hydrogen, an alkali, alkaline-earth or aluminum cation, or an ammonium, hydroxyethyl ammonium, or a tri(hydroxyethyl) ammonium ion, or a protonated form of an alkaline reacting amino acid. The active substance complex is also comprised of (B) at least one water-insoluble oil, wax or fat for improving the ability of keratin fibers to be combed and the feel thereof. The invention also relates to hair treatment preparations which contain this active substance complex.
The Centers for Disease Control and Prevention (CDC) have estimated that 25.6 million Americans aged 20 years or older have either been diagnosed or undiagnosed with diabetes mellitus. As such, it is crucial for patients to receive routine eye exams during their annual health assessment or diabetes follow-up visit with their primary care physician to check for diabetic retinopathy (DR). Of those Type 2 patients with a known duration of diabetes of less than 5 years, DR was diagnosed in 40% of patients taking insulin and 24% of patients not taking insulin. These percentages are especially concerning since data presented by Schoenfeld and colleagues indicates that approximately 35% of Americans with diabetes mellitus do not receive timely and recommended eye care to detect and treat their DR.10 Reasons for noncompliance include transfer to a retinal specialist, limited personal mobility, and insurance. In addition, patients regularly fail to follow-up with their ophthalmologist or optometrist due to the lack of visual symptoms-the lack of symptoms does not exclude the possibility of early diabetic retinopathy. Per the American Diabetes Association (ADA) guidelines, it is recommended that all Type 2 patients receive annual dilated eye exams. These eye exams must be completed by a knowledgeable and experienced eye care professional (i.e. ophthalmologist or optometrist). Early detection of DR and the preventative effects of therapy is an important aspect for long term vision outcomes.

The long-term goal is to improve the detection of diabetic retinopathy through better-quality measures of patient compliance and screening protocols in the prime care clinic. It is hypothesized that in type II diabetic patients without documented retinal pathology, a hand-held non-mydriatic fundus camera is superior to a referred dilated eye exams for the screening and detection of DR.
The active ingredient in pantoprazole sodium delayed-release tablets, USP is a substituted benzimidazole, sodium salt of 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion. Its molecular formula is C16H14F2N3NaO4S x 1.5 H2O, with a molecular weight of 432.36. The structural formula is:

Pantoprazole sodium sesquihydrate is a white to off-white crystalline powder and is racemic. Pantoprazole has weakly basic and acidic properties. Pantoprazole sodium sesquihydrate is freely soluble in water, very slightly soluble in phosphate buffer at pH 7.4, and practically insoluble in n-hexane.

The stability of the compound in aqueous solution is pH-dependent. The rate of degradation increases with decreasing pH. At ambient temperature, the degradation half-life is approximately 2.8 hours at pH 5 and approximately 220 hours at pH 7.8.

Pantoprazole sodium, USP is supplied as a delayed-release tablet, available in two strengths (20 mg and 40 mg).

Each pantoprazole sodium delayed-release tablet, USP contains 45.10 mg or 22.55 mg of pantoprazole sodium sesquihydrate (equivalent to 40 mg or 20 mg pantoprazole, respectively) with the following inactive ingredients: ammonium hydroxide, anhydrous sodium carbonate, black iron oxide, calcium stearate, crospovidone, hypromellose, mannitol, methacrylic acid copolymer, povidone, propylene glycol, shellac glaze, titanium dioxide, triethyl citrate and yellow iron oxide.

Pantoprazole sodium, USP complies with Related Compounds Test 2.

Pantoprazole sodium delayed-release tablets USP, 20 mg and 40 mg, meet USP Dissolution Test 3.
Curative resective is well-accepted as the predominant treatment for hepatocellular carcinoma (HCC) patients. Unfortunately, the long-term prognosis remains poor due to frequent postoperative recurrence, especially in HCC patients with portal vein tumor thrombus (PVTT). When PVTT invades into the portal vein system, tumor cell spreads and distributes along with the portal vein and its branches,thus resulting in intra-hepatic micro-metastasis which contributes to early recurrence for patients following curative resection. Postoperative adjuvant interventions include TACE, antiviral therapy, immunotherapy, local radiotherapy were applied to prevent recurrence. However, the efficacy and safety of these regimens remains unsatisfactory. Thus new therapeutic strategy remains to be investigated. This study is to investigate the efficacy and safety of Folfox4 chemotherapy regimen to prevent early recurrence for HCC patients with PVTT following curative resection.